Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
PreOmics logo — SETTING THE STANDARD FOR PROTEIN ANALYSIS

PreOmics

SETTING THE STANDARD FOR PROTEIN ANALYSIS

Founded 2016 Germany Germany 56 employees Series B Total: $16.85M Analytics, Biotechnology +1

General Information

Company Name PreOmics
Founded Year 2016
Location Germany Germany
Employees 56
Industries Analytics, Biotechnology, Productivity
Funding Stage Series B
Business Model B2B, Platform, B2G
Revenue Model Product Sales, One Time Purchase, Licensing
Social

BounceWatch is an independent company data service, not affiliated with PreOmics. To contact PreOmics, visit preomics.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does PreOmics compare?

A PDF of PreOmics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting PreOmics soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About PreOmics

PreOmics, founded in 2016 and headquartered in Germany, has become a pivotal part of the Biognosys Group as of 2025. The company's slogan, "SETTING THE STANDARD FOR PROTEIN ANALYSIS," highlights its core focus on enhancing proteomics through innovation and high-performance solutions.

The Biognosys Group, which includes PreOmics, Biognosys, and biocrates, is leading the charge in multiomics, integrating cutting-edge consumables, software, and instruments. This synergy delivers seamless mass spectrometry workflows. Their vendor-neutral approach broadens compatibility across major platforms, driving open collaboration in the scientific community.

PreOmics received a Series B investment of €13.50M in January 2022, backed by Bruker Corp.. This support underscores a strong alignment with strategic growth in the analytics and biotechnology sectors, offering scalable and flexible business models that adapt to diverse laboratory needs.

Business keywords: Proteomics, Mass Spectrometry, Multiomics, Metabolomics, Lipidomics, Consumables, Scientific Software, Research Tools, Vendor-neutral Solutions, CRO Services, Sample Preparation, Bioanalysis, LC-MS, Protein Analysis, Biotechnology Innovation

Services & Products

Sample preparation kits for proteins and peptides
Protein and peptide data analysis software
Automated sample preparation platforms
Liquid chromatography solutions

Target Customers

Research laboratories Biotechnology companies Academic institutions Pharmaceutical companies

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Series B €13.50M 1
Bruker Corp.
Bruker Corp.
01 Jan 2022
Series A €3.30M 3
HTGF Think.Health Ventures
HTGF, Think.Health Ventures +1
01 Dec 2018
Support Program $50.00K 4
Max Planck Institute for Biological Intelligence, Max Planck Institute of Biochemistry +2
01 Aug 2016

PreOmics Alternatives & Competitors

View All Alternatives
PreOmics vs
Allumiqs
Allumiqs Canada

Bold science. Beyond data. Better together.

Debt Financing
33 employees
Analytics, Biotechnology
Compare PreOmics vs Allumiqs
PreOmics vs
Scale Biosciences
Scale Biosciences United States

Boldly go where your single cell research takes you.

Acquired
10 employees
Analytics, Biotechnology
Compare PreOmics vs Scale Biosciences
PreOmics vs
NuGEN Technologies
NuGEN Technologies

Innovative genomics solutions ensuring accurate and reproducible results for pioneering scientific r...

Debt Financing
Analytics, Biotechnology
View all alternatives

FAQ About PreOmics

SETTING THE STANDARD FOR PROTEIN ANALYSIS
PreOmics was founded in 2016.
PreOmics is headquartered in Germany.
PreOmics operates in Analytics, Biotechnology and Productivity. Its work centres on Proteomics, Mass Spectrometry, Multiomics and Metabolomics. Its customers include Research laboratories, Biotechnology companies and Academic institutions.
PreOmics has a B2B, Platform and B2G business model. Its revenue comes from Product Sales, One Time Purchase and Licensing.
PreOmics has approximately 56 employees.
PreOmics has completed 3 funding rounds, raising a total of $16.85M. The latest funding stage is Series B.
PreOmics offers: Sample preparation kits for proteins and peptides, Protein and peptide data analysis software, Automated sample preparation platforms, Liquid chromatography solutions.
Top alternatives and competitors to PreOmics include Allumiqs, Scale Biosciences, NuGEN Technologies, Biametrics GmbH. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
PreOmics and Allumiqs are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for PreOmics, https://bouncewatch.com/company/preomics, updated 14 May 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout